Pleiotropic effects of statins in the diseases of the liver

Figure 1 Association between total cholesterol and hepatitis B virus DNA load[43]. With permission from Elsevier. HBV: Hepatitis B virus.

Figure 2 Dotplots for vFW: Ag according to fibrosis stage showing mean values and IQR. ^bP < 0.001 for all fibrosis stages, F3 vs F4 ^dP < 0.0001[54]. With permission from John Wiley and sons.

Figure 3 Receiver operating characteristics curves for vWF:Ag, VITRO score and FORNS in the diagnosis of cirrhosis (F4). AUC vWF:Ag = 0.835, VITRO score = 0.893 and FORNS = 0.874 (P = NS)[54]. With permission from John Wiley and sons.

Figure 4 Pathogenesis of hepatocellular carcinoma and targets for chemopreventive agents. Tyrosin kinase associated receptor pathways induce MAPK and PI3K-Akt kinase pathways in > 50% of HCCs. The resulting disruption of the mTOR pathwayh is seen in 40%-50% of cases of HCC, leading to inactivation of tumour suppressors such as PTEN. Statins block post-translational prenylation of Ras/Raf proteins, inhibit the activation of the proteasome pathway, limiting the degradation of the cyclin-dependent kinase inhibitors p21 and p27, and block Myc phosphorylation. Metformin activates AMPK, which inhibits the mTOR pathway. Thiazolidinediones inhibit the ubiquitin-proteasome system and extracellular signal-regulated kinase pathway. Insulin and sulphonylureas might promote hepatocarcinogenesis by increasing IGFR1 activity, enhancing growth-factor-dependent cell proliferation. AMPK: Adenosine monophosphate-activated protein kinase; HCC: Hepatocellular carcinoma; IGFR1: Insulin-like growth factor receptor 1; IR: Insulin receptor; MAPK: Ras mitogenactivated protein kinase; mTOR: Mammalian target of rapamycin; PI3K: Phosphatidylinositol 3-kinase; PPAR-γ: Peroxisome proliferator activated receptor γ[75]. With permission from Nature publishing group.

Figure 5 Overall meta-analysis of statin use and liver cancer risk[86].